<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/234135-meldonium-salts-process-for-their-preparation-and-pharmaceutical-composition-comprising-them by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:05:24 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 234135:MELDONIUM SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM .</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">MELDONIUM SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THEM .</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention discloses Meldonium salts having the general formula : X-(CH3) 3N+NHCH2CH2COOH wherein X- is an anion selected from the group consisting of dihydrogen phosphate, hydrogen fumarate and orotate anions. The invention is also for preparation of said salts and pharmaceutical composition comprising them.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>DESCRIPTION<br>
Meldonium Salts, Process for Their Preparation and<br>
Pharmaceutical Composition Comprising Them<br>
TECHNICAL FIELD<br>
The present invention relates to 3-(2,2,2-trimethyIhydrazinium)propionate salts<br>
of the general formula X"(CH3)3N+NHCH2CH2COOH where X" is an acid anion<br>
selected from the group of acid phosphate, acid fumarate, acid oxalate, acid maleate<br>
and/or acid pamoate, orotate, galactarate, sulfate, dichloroacetate, acid galactarate,<br>
fumarate, taurate, maleate, acid aspartate, creatinate, acid sulfate, magnesium<br>
succinate, acid citrate, citrate, succinate, acid succinate, adipinate, acid tartrate and<br>
lactate, which distinguish from 3-(2,2,2-trimethylhydrazinium) propionate dihydrate<br>
by low hygroscopicity and/or increased thermal stability and/or lasting action. This<br>
invention relates also to the method of such salt preparation and to pharmaceutical<br>
formulations containing the said salts.<br>
BACKGROUND OF THE INVENTION<br>
3-(2,2,2-Trimethylhydrazinium) propionate is disclosed in US Patent<br>
No.4481218.<br>
It is well known that 3-(2,2,2-trimethylhydrazinium) propionate as dihydrate<br>
(this substance being known under its International Nonproprietary Name of<br>
Meldonium) is widely used for controlling carnitine and gamma-butyrobetaine<br>
concentration ratio and consequently the speed of fatty acid beta-oxidation in the body<br>
(Dambrova M., Liepinsh E., Kalvinsh I. Mildronate: cardioprotective action through<br>
carnitine-lowering effect. Review. // Trends Cardiovasc.Med. - 2002. - Vol. 12, N.6.<br>
- P. 275-279. Rupp FL, Zarain-Herzberg A., Maisch B. The use of partial fatty acid<br>
oxidation inhibitors for metabolic therapy of angina pectoris and heart failure // Herz,<br>
2002. - Vol. 27, N.7. - P. 621-636. Mildronate, Met-88. Drugs Fut. 2001, 26(1),<br>
p.82).<br>
Due to these properties, Meldonium (registered with the trade mark of<br>
,,MILDRONATS®" , "MILDRONATE®", "MPOHAT®") is extensively applied<br>
in medicine as an anti-ischemic un stress-protective drug in treating various cardiovascular<br>
diseases and other pathologies involving tissue ischemia (R.S.Karpov,<br>
O.A.Koshelskaya, A.V.Vrublevsky, A.A.Sokolov, A.T.Teplyakov, I.Skarda,<br>
V.Dzerve, D.Klintsare; A.Vitols, I.Kalvinsh, L.Matveyeva, D.Urbane. Clinical<br><br>
efficacy and safety of Mildronate in patients with ischemic heart disease and chronic<br>
heart failure. Kardiologiya, 2000 , Vol.6, - P.69-74.)<br>
However, Meldonium as dihydrate has essential drawbacks, the first of which<br>
consists in its rather high hygroscopiciry. Already after 24 hours maintenance at 100%<br>
air humidity, Meldonium mass is increased by 10% because of water absorption, the<br>
substance being transformed into a syrup.<br>
Other essential drawback of Meldonium is caused by the half-elimination period<br>
equalling 4-10 hours for humans while this drug must be used 2-4 times daily in the<br>
clinic (V.Dzerve. Mildronats. PAS "Grindeks", 1999, p.l), though it is longer in trials<br>
on rats (K.Yoshisue, Y.Yamomoto, K.Yoshida, M.Saeki, Y.Minami, Y.Esumi,<br>
Y.Kawaguchi. Pharmacokinetics and biological fate of 3-(2,2,2-<br>
trimethylhydrazinium)propionate (MET-88), a novel cardioprotective agent, in rats.<br>
Drug Metabolism and Disposition, vol.28, No6, 687-694).<br>
As Meldonium dihydrate is unsuitable for single daily oral introduction, it was<br>
one of the aims of the present invention to find other pharmacologically acceptable<br>
Meldonium forms which would be applicable for single daily use. It is generally<br>
known that amino acid betaine salts usually have good solubility in water. If<br>
pharmacologically acceptable acids are selected, resorption and elimination<br>
pharmacokinetics and biological activity of these salts normally does not much differ<br>
from the parameters of the initial compound.<br>
Besides, Meldonium is not very stable: while heated, it fast loses the water of<br>
the crystal hydrate. In turn, the anhydrous form of Meldonium is unstable and<br>
extremely hygroscopic. In such form, this compound soon becomes coloured and gets<br>
a specific annoying odour. Thus, the hygroscopicity and thermal non-stability of<br>
Meldonium dihydrate are significant disadvantages restricting the possibilities of<br>
preparing different oral and external drug dosage forms from this compound.<br>
Furthermore, Meldonium dihydrate is actively dehydrated at temperatures so low as<br>
40-45°C. This means that sure storage of Meldonium dosage forms containing crystal<br>
hydrate is rather embarrassing in countries with hot climate.<br>
Because Meldonium dihydrate is not readily applicable for producing drug oral<br>
dosage forms, it was a further object of this invention to find other pharmacologically<br>
acceptable salts of Meldonium which would lack hygroscopicity or/and, be thermally<br>
stable and could be stored in any climatic zone for a long time.<br><br>
DETAILED DESCRIPTION OF THE INVENTION<br>
For most Meldonium salts, their pharmacokinetic properties practically do not<br>
differ from those described for Meldonium. Therefore the use of these salts for<br>
preparing pharmaceutical compositions seemingly have no advantage as compared to<br>
Meldonium.<br>
To our surprise, we suddenly found that Meldonium salts of some<br>
pharmaceutically acceptable polybasic acids are an exception in this respect; although<br>
readily soluble in water, they essentially differ from Meldonium by their<br>
pharmacokinetic and pharmacodynamic properties.<br>
It was an astonishing discovery since no theoretical argument exists why<br>
Meldonium salts, which are easily soluble in water should have resorption and<br>
elimination speed different from that of Meldonium.<br>
Nevertheless, we succeeded in finding among the above salts some specific<br>
Meldonium salts with appropriate pharmacokinetics and pharmacodynamics allowing<br>
their single daily use; they are: X(CH3)3N+NHCH2CH2COOH where X" is the anion<br>
of acids is selected from the group of mono-substituted fumaric acid, mono-<br>
substituted phosphoric acid, mono-substituted oxalic acid, mono-substituted maleic<br>
acid un mono- and/or di-substituted galactaric, pamoic acids and orotic acid.<br>
It is common knowledge that betaines of amino acids are commonly relatively<br>
stable substances. It is well known that these compounds are readily soluble in water<br>
and the biological activity of their pharmacologically acceptable salts usually does not<br>
differ from that of the initial compound.<br>
However, Meldonium and monobasic, dibasic as well as tribasic<br>
pharmaceutically acceptable acid salts have equal or even higher hygroscopicity than<br>
Meldonium itself. Moreover, many of them cannot be prepared in crystalline form at<br>
all because they form syrups containing variable quantity of water.<br>
The salts of both strong and weak acids, viz. Meldonium sulfate, hydrogen<br>
chloride, acetate, lactate, citrate as well as salts of many other pharmaceutically<br>
acceptable acids are hygroscopic. Consequently, using these salts for preparation of<br>
pharmaceutical compositions for oral use is deemed lacking preference to that of<br>
Meldonium.<br>
We noticed completely unexpectedly that Meldonium salts of some<br>
pharmaceutically acceptable polybasic acids are exceptional in this regard; they<br><br>
proved to be practically non-hygroscopic though easily soluble in water. We observed<br>
that these compounds are also very stable while maintained at both room temperature<br>
and temperatures up to at least 50 centigrade over a long period of time. Similarly we<br>
gained the unanticipitated result that such specific monobasic acid as orotic acid<br>
forms a non-hygroscopic Meldonium salt, too. All of 1he claimed salts proved more<br>
stable thermally than Meldonium.<br>
Orally administered Meldonium is easily bioavailable also from these salts,<br>
therefore these salts are much more suitable for preparing various drug dosage forms<br>
than the hygroscopic and thermally unstable Meldonium. It was an astounding<br>
discovery because no theoretical underpinning suggests any difference of Meldonium<br>
orotate or polybasic acid salts, which are also readily soluble in water, from other<br>
salts as to hygroscopicity.<br>
Since they are not hygroscopic and/or have increased thermal stability, these<br>
salts can be easily handled and are favourably suitable for manufacturing solid<br>
administration forms. Their aqueous solutions are less acid than those of the<br>
corresponding chlorides: consequently these salts are also more suitable for<br>
manufacturing injectable administration forms.<br>
The following non-limiting examples illustrate the preparation of salts according<br>
to the present invention.<br>
EXAMPLE 1<br>
The following methods may be applied for the preparation of these salts.<br>
Meldonium is dissolved in water or other appropriate solvent, an equimolar quantity<br>
of a polybasic acid selected from the group of fumaric acid, phosphoric acid, aspartic<br>
acid, citric acid, lactic acid, maleic acid, oxalic acid, or orotic acid (the latter is taken<br>
in semi-molar quantity) is added, and the mixture is stirred at temperature from 20 to<br>
50°C till the corresponding salt is formed. At the second technological stage,<br>
Meldonium salts are evaporated to dryness if necessary. At the third technological<br>
stage, in case of need the obtained salts are recrystallised from a suitable solvent.<br>
EXAMPLE 2<br>
The said salts can also be prepared from the corresponding salts of Meldonium<br>
production intermediates, viz.	methyl- or ethyl-esters of 3(2,2,2,-<br>
trimethylhydrazinium) propionate, the latter being heated together with the<br>
corresponding acids in aqueous or aqueous-alcoholic solutions, and subsequent<br><br>
treatment, eduction and purification being performed by analogy with the first method<br>
of preparation.<br>
EXAMPLE 3<br>
Method of salt preparation from meldonium dihydrate. Meldonium and the<br>
corresponding acid are dissolved in a small quantity of water at 40-50°C under<br>
stirring. The obtained solution is evaporated in vacuum at 40-50°C. Acetone or<br>
acetonitrile is added to the formed mass (what predominantly is viscous syrup), and<br>
the mixture is grated. The precipitated crystalline mass is stirred in acetone or<br>
acetonitrile during several hours, filtered off, washed with acetone or acetonitrile,<br>
dried in vacuum at room temperature.<br>
Sample hygroscopicity was tested by H2O content determination before the test<br>
and after 24 hours maintenance at 100% humidity (keeping in a closed vessel over<br>
water). On such conditions, Meldonium absorbs 10% water (as to mass increase)<br>
during 24 hours. Water content was determined by titration by Fischer's method; in<br>
cases of syrup formation water content is determined by sample mass increase.<br>
The claimed invention is illustrated by, but not restricted to the following<br>
examples of salts obtained by the above method:<br>
EXAMPLE 4<br>
Meldonium orotate (1:1). Mp. 211-214°C. 1H NMR spectrum (D2O), 5, ppm:<br>
2.56 (2H, t, CH2COO-); 3.29 (2H, t, CH2N); 3.35 (9H, s, Me3N+); 6.18 (IH, s, -CH=).<br>
Found, %: C 43.78; H6.01; N 18.48. Calculated, %: C 43.71; H 6.00; N 18.53.<br>
Initially H2O content in the sample was 0.3919%; during 24 hours at 100% humidity<br>
it remains unchanged.<br>
EXAMPLE 5<br>
Meldonium dihydrogen phosphate (1:1). Mp.l58-160°C. lH NMR spectrum (D2O), 5, ppm:<br>
2.60 (2H, t, CH2COO-); 3.31 (2H, t, CH2N); 3.35 (9H, s, Me3N+). Found, %: C 29.64;<br>
H 7.05; N 11.33 Calculated, %: C 29.51; H 7.02; N 11.47. Initially H2O content in the<br>
sample was 0.0762%; during 24 hours at 100% humidity it remains unchanged.<br>
EXAMPLE 6<br>
Meldonium hydrogen fumarate (1:1). Mp. 140-142°C. 1H NMR spectrum, S, ppm: 2.57<br>
(2H, t CH2); 3.29 (2H, t, CH2); 3.35 (9H, s, Me3N+), 6.72 (2H, s, -CH=CH-). Found.<br>
%: C 45,46; H 6,94; N 10,72. Calculated, %: C 45,80; H 6,92; N 10.68. Initially H2O<br><br>
content in the sample was 0.18%; during 24 hours a.t 100% humidity it remains<br>
unchanged.<br>
EXAMPLE 7<br>
Meldonium oxalate (1:1). Mp. 123-125°C . 1H NMR spectrum (D2O), δ, ppm:<br>
2.61 (2H, t, CH2COO-); 3.30 (2H, t, CH2N); 3.35 (9H, s, Me3N+). Found, %: C 40.86;<br>
H 6.82; N 11.78 Calculated, %: C 40.68; H 6.83; N 11.86. Initially H2O content in<br>
the sample was 0.1661%; after 24 hours maintenance at 100% humidity it was<br>
3.1211%.<br>
EXAMPLE 8<br>
Meldoniuma maleate (1:1). Mp. 98-100°C lHNMR spectrum (D2O), 5, ppm:<br>
2.60 (2H, t, CH2COO-); 3.31 (2H, t, NCH2); 3.35 (9H, s, Me3N+); 6.35 (2H, s, -<br>
CH=CH-). Found, %: C 45.93; H 6.95; N 10.65. Computational, %: C 45.80; H 6.92;<br>
N 10.68. Initially H2O content in the sample was 0.387%; after 24 hours maintenance<br>
at 100% humidity it was 4.6844%.<br>
EXAMPLE 9<br>
Meldonium mucate (galactarate; 2:1; x H2O). Mp.l52-154°C. 1HNMR spectrum<br>
(D2O), δ, ppm: 2.46 (4H, t, 2 x CH2COO-); 3.26 (4H, t, 2 xNCH2); 3.35 (18H, s,<br>
2 x Me3N+); 3.98 un 4.31 - two singlets of low intensity, protons of mucic acid.<br>
Found, %: C 42.13; H 7.58; N 10.77. Calculated, %: C 41.53; H 7.75; N 10.76.<br>
Initially H2O content in the sample was 3.0414%; after 2.4 hours maintenance at 100%<br>
humidity it was 7.6830%.<br>
EXAMPLE 10<br>
Meldonium pamoate (1:1; x H2O). Meldonium (5.46 g, 30 mmol) and pamoic<br>
acid (5.82 g, 15 mmol) are mixed with water and acetone (15 + 15 ml), the formed<br>
suspension is evaporated, 30-40 ml toluene is added to the residual viscous mass, it is<br>
grated, and evaporation is repeated. If the residue is insufficiently dry, treatment with<br>
toluene is repeated. Mp. 128-133°C (decomp.). ]H NMR spectrum (DMSO-d6),<br>
δ, ppm: 2.41 (2H, t, CH2COO-); 3.14 (2H, t, CH2N); 3.25 (9H, s, Me3N+); 4.75 (2H, s,<br>
-CH2-(pam.)); 7.12 (2H, t, Haram); 7.26 (2H, td, Harom); 7.77 (2H, d, Harom); 8.18 (2H, d,<br>
Harom); 8.35 (2H, s, Harom). Found, %: C 62,90; H 5,83; N 4,98. Calculated, %: C<br>
63,07; H 5,84; N 5,07. Initially H2O content in the sample was 1.71%; after 24 hours<br>
maintenance at 100% humidity sample mass increased by 9% due to absorbed water.<br>
EXAMPLE 11<br><br>
Meldonium sulfate (2:1). Tm 80-182°C (decomp.)- 1H NMR spectrum (D2O),<br>
δ, ppm: 2.60 (4H, t, 2 x CH2COO-); 3.30 (4H, t, 2 x CH2N); 3.35 (18H, s,<br>
2 x Me3N+). Found, %: C 37.08; H 7.73; N 14.29; S 8.20. Calculated, % : C 36.91; H<br>
7.74; N 14.35; S 8.21. Initially H2O content in the sample was 0.313%; after 24 hours<br>
maintenance at 100% humidity sample mass increased by 11.8% due to absorbed<br>
water.<br>
EXAMPLE 12<br>
Meldonium dichloroacetate (1:1). Mp. 86-88°C. 1H NMR spectrum (D2O), δ,<br>
ppm: 2.61 (2H, t, CH2COO-); 3.31 (2H, t, CH2N); 3.35 (9H, s, Me3N+); 6.05 (1H, s, -<br>
CHCl2). Found, %: C 35.13; H 5.85; N 10.10. Calculated, %: C 34.92; H 5.86; N<br>
10.18. Initially H2O content in the sample was 1.17%; after 24 hours maintenance at<br>
100% humidity sample mass increased by 12% due to absorbed water.<br>
EXAMPLE 13<br>
Meldonium mucate (galactarate; 1:1). Mp. 152-154°C. 1H NMR spectrum<br>
(D2O), δ, ppm: 2.47 (2H, t, CH2COO-); 3.26 (2H, t, CH2N); 3.35 (9H, s, Me3N+); 3.71<br>
and 3.98 - two singlets of low intensity, protons of the slightly soluble mucic acid.<br>
Found, %: C 40.22; H 6.75; N 7,75%. Calculated, %: C 40,22; H 6,79; N 7,86.<br>
Initially H2O content in the sample was 1.98%; after 24 hours maintenance at 100%<br>
humidity it was 12.8 % .<br>
EXAMPLE 14<br>
Meldonium fumarate (2:1). Mp. 156-158°C. ]H NMR spectrum (D2O), 8, ppm:<br>
2.53 (4H, t, 2 x CH2(meld)); 3.29 (4H, t, 2 x CH2(meld)); 3.35 (18H, s, 2 x Me3N+); 6.65<br>
(2H, s, -CH=CH-(fum.ac.)). Found, %: C 46.68; H 7.91; N 13.69. Calculated, %: C<br>
47.05; H 7.90; N 13.72. Initially H2O content in the sample was 1.5136%; after 24<br>
hours maintenance at 100% humidity it was 13.4707%.<br>
EXAMPLE 15<br>
Meldonium 2-aminoethane sulfonate (taurate; 1:1; x 1.5H2O). Mp. 190-193°C<br>
(with decomp.). 1H NMR spectrum (D2O), δ, ppm: 2.38 (2H, t, CH2COO-); 3.18-3.30<br>
(4H, m, NCH2(meid.) + CH2(taur.)); 3.34 (9H, s, Me3N+); 3,42 (2H, t, CH2(taur.)). Found,<br>
%: C 32.40; H 8.16; N 13.98; S 10.60. Calculated, %: C 32.21; H 8.11; N 14.08; S<br>
10.75. Initially H2O content in the sample was 9,4824%; after 24 hours maintenance<br>
at 100% humidity it was 17.0854%.<br><br>
EXAMPLE 16<br>
Meldonium maleate (2:1). Mp. 104-106°C. 1H NMR spectrum (D2O), δ, ppm:<br>
2.54 (4H, t, CHaCOO-); 3.30 (4H, t, CH2N); 3.35 (18H, s, Me3N+); 6.42 (2H, s,<br>
-CH=CH-). Found, %: C 46.59; H 7.88; N 13.50. Calculated: C 47.05; H 7.90; N<br>
13.72. Initially H2O content in the sample was 1,3595%; after 24 hours maintenance<br>
at 100% humidity sample mass increased by 18% due to absorbed water.<br>
EXAMPLE 17<br>
Meldonium L-(+)-aspartate (1:1; x2H2O). Mp. 146-148°C. 1H NMR spectrum<br>
(D2O), δ, ppm: 2.49 (2H, t, CH2COO-); 2.70-2.99 (2H, m, CH2(asp)) 3.27 (2H, t,<br>
CH2N); 3.35 (9H, s, MesN+); 3.95 (1H, dd, CHNH2). Found, %: C 37.71; H 7.85;<br>
N 13.03. Calculated, %: C 38.09; H 7.99; N 13.33. Initially H2O content in the sample<br>
was 12.5%; after 24 hours maintenance at 100% humidity sample mass increased by<br>
18% due to absorbed water.<br>
EXAMPLE 18<br>
Meldonium creatinate (1:1; x3H2O). Mp. 227-228°C (decomp.). 1H NMR<br>
spectrum (D2O), δ, ppm: 2.38 (2H, t, CH2COO-); 3.03 (3H, s, NMe(oreatlne)); 3.22 (2H,<br>
t, CH2N); 3.35 (9H, s, MesN+); 3.92 (2H, s, NCH2(creatine,). Initially H2O content in the<br>
sample was 15.8%; after 24 hours maintenance at 100% humidity sample mass<br>
increased by 18% due to absorbed water.<br>
EXAMPLE 19<br>
Meldonium sulfate (1:1). Tm 98-100°C. 1H NMR spectrum (D2O), δ, ppm: 2.62<br>
(2H, t, CH2COO-); 3.31 (2H, t, CH2N); 3.35 (9H, s, Me3N+). Found, % C: C 29.23; H<br>
6.57; N 11.17; S 13.10. Calculated: C 29.50; H 6.60; N ] 1.47; S 13.13. Initially H2O<br>
content in the sample was 1.4189%; after 24 hours maintenance at 100% humidity<br>
sample mass increased by 20% due to absorbed water.<br>
EXAMPLE 20<br>
Meldonium magnesium succinate (1:1:1; x2H2O). (see Meldonium-magnesium<br>
tartrate). Mp. 135-140°C (decomp.). 1HNMR spectrum (D2O), δ, ppm: 2.39 (2H, t,<br>
CH2COO-); 2.46 (4H, s, -CH2-CH2-(succin.ac,)); 3.22 (2H, t, CH2N); 3.35 (9H, s,<br>
MeaN+). Found, %: C 36.66; H 7.28; N 8.37. Calculated: C 37.23; H 6.87; N 8.68.<br>
Initially H2O content in the sample was 10.1215%; after 24 hours maintenance at<br>
100% humidity sample mass increased by 20% due to absorbed water.<br>
EXAMPLE 21<br><br>
Meldoniurn magnesium citrate (1:1:1; x2H2O) (see Meldonium-magnesium<br>
tartrate). Mp. 195-200°C (decomp.). 2HNMR spectrum (D2O), δ, ppm: 2.48 (2H, t,<br>
CH2COO-); 2.75 (4H, dd, 2xCH2(citr.)); 3.26 (2H, t, CH2N); 3.34 (9H, s, Me3N+).<br>
Found, %: C 36.58; H 6.09; N 6.96. Calculated: C 36.34; H 6.10; N 7.06. Initially<br>
H2O content in the sample was 9.45%; after 24 hours maintenance at 100% humidity<br>
the sample diffused.<br>
EXAMPLE 22<br>
Meldonium citrate (1:1). Mp. 90-95°C (decomp.). lH NMR spectrum (D2O), δ,<br>
ppm: 2.56 (2H, t, CH2COO-); 2.85 (4H, dd, 2xCH2(citr)); 3.28 (2H, t, CH2N); 3.35<br>
(9H, s, Me3N4).<br>
EXAMPLE 23<br>
Meldonium citrate (2:1). Mp. 101-107°C (decomp.). 1H NMR spectrum<br>
(D2O), 5, ppm: 2.51 (4H, t, 2xCH2COO-); 2.81 (4H, dd, 2xCH2(citr.)); 3.26 (4H,<br>
t, 2xCH2N); 3.35 (18H, s, 2x Me3N+).<br>
EXAMPLE 24<br>
Meldonium succinate (1:1). Mp. 95-100°C (decomp.).1H NMR spectrum (D2O),<br>
5, ppm: 2.51 (2H, t, CH2(meldon.)); 2.60 (4H, s, -CH2-CH2-(succin.ac)); 3.27 (2H, t,<br>
CH2(meldon.)); 3.35 (9H, s, Me3N+).<br>
EXAMPLE 25<br>
Meldonium succinate (2:1). Mp. 103-107°C (decomp.).1H NMR spectrum<br>
(D2O), δ, ppm: 2.47 (4H, t, 2 x CH2(meldon.)); 2.59 (4H, s, -CH2-CH2-(succin.ac.)); 3.29<br>
(4H, t, 2 x CH2(meldon.)); 3.35 (18H, s, 2 x Me3N+).).<br>
EXAMPLE 26<br>
Meldonium adipinate (2:1). Mp. 110-114°C (decomp.).1H NMR spectrum<br>
(D2O), δ, ppm: 1.55-1.70 (4H, m, 2xCH2(adip.)); 2.28-2.39 (4H, m, 2xCH2(adip.)); 2.45<br>
(4H, t, 2xCH2(meIdon.)); 3.24 (4H, t,-2xCH2(meldon.)); 3.34 (18H, s, 2 x Me3N+).<br>
EXAMPLE 27<br>
Meldonium tartrate (1:1). Mp. 100-107°C (decomp.). 1H NMR spectrum (D2O),<br>
8, ppm: 2.57 (2H, t, CH2COO-); 3.29 (2H, t, CH2(meldon.)); 3.35 (9H, s, Me3N+); 4.55<br>
(2H, s, CH(tart.ac.)).<br>
EXAMPLE 28<br><br>
Meldonium lactate (1:1). Mp. 110-114°C (decomp.). 1H NMR spectrum (D2O),<br>
δ, ppm: 1.33-1.48 (3H, m, Me(lact.ac.)); 2.50 (2H, t, CH2COO-); 3.26 (2H, t, CH2(mildr.));<br>
3.35 (9H, s, Me3N+); 4.21 (1H, q, CH(lact.ac.)).<br>
This invention relates also to pharmaceutical formulations containing at least<br>
one of the Meldonium salts described herein as pharmaceutical active and<br>
pharmaceutically acceptable solid or liquid excipients used in drug dosage form<br>
production. Solid formulations suitable for producing dosage forms of oral<br>
introduction as well as syrups and solutions containing the claimed salts and<br>
excipients are preferable.<br>
In case when the active substance(s) is (are) inserted into tablets, caplets, pills,<br>
granules, powders, or capsules, they shall contain a Meldonium salt from 0,5 to 5 gr.<br>
per tablet, caplet, pill, capsule or one portion of powder or granules.<br>
The following non-limiting examples illustrate the pharmaceutical formulation<br>
of salts for solid formulation<br>
EXAMPLE 29 Formulation for manufacturing tablets:<br>
A Meldonium salt	500 mg<br>
according to the invention<br>
Starch	20 mg<br>
Talc	10 mg<br>
Ca-stearate	1 mg<br>
Total	531 mg<br>
The following non-limiting examples illustrate composition suitable for<br>
producing capsules is the following :<br>
EXAMPLE 30<br>
A Meldonium salt	500 mg<br>
according to the invention<br>
Starch	66mg<br>
Talc	26 mg<br>
Ca-stearate	3 mg<br>
Total	602 mg<br><br>
In case if the active(s) are introduced by injections or orally by means of drops,<br>
a syrup or beverage, the pharmaceutical formulation shall contain a Meldonium salt<br>
according to this invention in a ratio of 0,5 to 60% by weight and a pharmaceutically<br>
admissible solvent, e.g. distilled water, an isotonic, glucose or buffer solution or<br>
mixtures of them.<br>
The following non-limiting examples illustrate the pharmaceutical formulation<br>
of salts for injectable administration or/and orally administration:<br>
EXAMPLE 31<br>
Injection formulation:<br>
A Meldonium salt	500 mg<br>
according to the invention<br>
Water for injections	5ml<br>
EXAMPLE 32<br>
A syrup formulation:<br>
A Meldonium salt	25.00 mg<br>
according to the invention<br>
Methyl-p-hydroxybenzoate	0.20-0.60 g<br>
Propyl-p-hydroxybenzoate	0.01-0.1 g<br>
Propylene glycol	6.15-8.30g<br>
Sorbit	120.00-150.50 g<br>
Glycerine	10.00-15.00 g<br>
Purified water	108ml<br>
Total	250ml<br>
In case of trans-dernial application of the actrve(s), it's (their) content in an<br>
cream, gel, solution, ointment or plaster shall be 0.5-40% by weight.<br>
The following non-limiting examples illustrate the pharmaceutical formulation<br>
of salts for trans-dermal (local/topical) administration:<br>
EXAMPLE 33<br>
Gel formulation:<br>
A Meldonium salt	10,00%<br>
according to the invention<br><br>
12<br>
Sodium starch glycollate	4,00<br>
type C,<br>
Propylene glycol	2,00<br>
Fumaric acid	0,40<br>
Purified vater	83,40<br>
In the case the salt are administered rectally their content in a suppository or<br>
microenema accounts for 0.5 to 40 % by weight.<br><br>
We claim:<br>
1.	Meldonium salts having the general formula'<br>
X(CH3)3N+NHCH2CH2COOH<br>
wherein X' is an anion selected from the group consisting of dihydrogen<br>
phosphate, hydrogen fumarate and orotate anions.<br>
2.	A salt as claimed in claim 1 which is meldonium dihydrogen phosphate.<br>
3.	A salt as claimed in claim 1 which is meldonium hydrogen fumarate.<br>
4.	A salt as claimed in claim 1 which is meldonium orotate.<br>
5.	A process for producing the meldonium salts as claimed in any of claims 1 to 4<br>
which process comprises:<br><br>
(a)	dissolving in a manner known per se meldonium having the formula 3-<br>
(2,2,2-trimethyl hydrazinium) propionate in water or any other appropriate<br>
solvent;<br>
(b)	adding an equimolar quantity of a polybasic acid selected from the group<br>
consisting of fumaric acid, phosphoric acid, and orotic acid;<br>
(c)	stirring the mixture at a temperature of from 20 to 50°C until the<br>
corresponding salt is formed, and evaporating the meldonium salt formed in<br>
step (c) to dryness, if necessary; and optionally recrystallising it from a suitable<br>
solvent.<br><br>
6.	A pharmaceutical composition comprising one of the salts as claimed in any of<br>
claims 1 to 4 as an active ingredient, which composition is intended for oral or<br>
sublingual administration and is in the form of tablets, with or without coating,<br>
capsules, caplets, dragees, granules, powder or solution, which composition<br>
contains from 0.5 to 5 g of the active ingredient in every tablet, capsule,<br>
dragee, granule or powder dose, or in the form of a 0.5-40% by weight solution<br>
or syrup for oral administration.<br>
7.	The pharmaceutical composition as claimed in claim 6, wherein the<br>
pharmaceutically acceptable carrier is selected from the group consisting of<br>
one or more of the following members: stearic acid and its salts, lactose,<br>
glucose, saccharose, starch, talc, vegetable oils, polyethylene glycols,<br>
microcrystalline cellulose, aerosil, aromatizers, flavoring agents, colorants,<br>
ethyl alcohol and water.<br>
8.	A pharmaceutical composition comprising one of the salts as claimed in any of<br>
claims 1 to 5 as an active ingredient which composition is intended for<br>
parenteral administration and is in the form of a solution for injection, which<br>
composition contains from 0.5 to 40% by weight of the active ingredient and a<br>
pharmaceutically acceptable solvent.<br>
9.	The pharmaceutical composition as claimed in claim 8, wherein the pharma-<br>
ceutically acceptable solvent is selected from the group consisting of one or<br>
more of the following members, distilled water, isotonic solution, buffer solution<br>
and glucose solution.<br>
10.	A pharmaceutical composition comprising one of the salts as claimed in any of<br>
claims 1 to 5 as an active ingredient which composition is intended for<br>
transcutaneous administration and is in the form of an ointment, cream, gel,<br>
solution or plaster, which composition contains from 0.5 to 40% by weight of<br>
the active ingredient and a pharmaceutically acceptable carrier<br>
11.	The pharmaceutical composition as claimed in claim 10, wherein the<br>
pharmaceutically acceptable carrier is selected from the group consisting of<br>
one or more of the following members, water, polyethylene glycols 400, 1500<br>
and 4000, vegetable oils, fats, glycerine, preservants, emulgators, stabilizers,<br>
norous polymer material, dimethylsulphoxide, alcohol and water.<br><br>
12.	A pharmaceutical composition comprising one of the salts as claimed in any of<br>
claim 1 to 5 as an active ingredient which composition is intended for rectal<br>
administration and is in the form of suppositories or microenema, which<br>
composition contains from 0.5 to 40% by weight of the active ingredient and a<br>
pharmaceutically acceptable carrier.<br>
13.	The pharmaceutical composition as claimed in claim 12, wherein the<br>
pharmaceutically acceptable carrier is selected from the group consisting of<br>
one or more of the following members: water, polyethylene glycols 400, 1500<br>
and 4000, vegetable oils, fats, glycerine, preservants, emulgators and<br>
stabilizers.<br><br>
The invention discloses Meldonium salts having the general formula : X-(CH3)<br>
3N+NHCH2CH2COOH wherein X- is an anion selected from the group consisting of<br>
dihydrogen phosphate, hydrogen fumarate and orotate anions. The invention is also for<br>
preparation of said salts and pharmaceutical composition comprising them.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1hc3NpZ25tZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1pbnRlcm5hdGlvbmFsIHNlYXJjaCBhdXRob3JpdHkucGRm" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-international search authority.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAwOTAta29sbnAtMjAwNi1wY3QgZm9ybXMucGRm" target="_blank" style="word-wrap:break-word;">00090-kolnp-2006-pct forms.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAtS09MTlAtMjAwNi0oMTMtMDEtMjAxMiktRk9STS0yNy5wZGY=" target="_blank" style="word-wrap:break-word;">90-KOLNP-2006-(13-01-2012)-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAtS09MTlAtMjAwNi1DT1JSRVNQT05ERU5DRS4uMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">90-KOLNP-2006-CORRESPONDENCE..1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAtS09MTlAtMjAwNi1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">90-KOLNP-2006-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAtS09MTlAtMjAwNi1GT1JNIDI3LjEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">90-KOLNP-2006-FORM 27.1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAtS09MTlAtMjAwNi1GT1JNIDI3LnBkZg==" target="_blank" style="word-wrap:break-word;">90-KOLNP-2006-FORM 27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWFzc2lnbm1lbnQucGRm" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWNvcnJlc3BvbmRlbmNlLnBkZg==" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWV4YW1pbmF0aW9uIHJlcG9ydC5wZGY=" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWZvcm0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWZvcm0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWZvcm0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLWdwYS5wZGY=" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLXJlcGx5IHRvIGV4YW1pbmF0aW9uIHJlcG9ydC5wZGY=" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=OTAta29sbnAtMjAwNi1ncmFudGVkLXNwZWNpZmljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">90-kolnp-2006-granted-specification.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="234134-process-for-purification-treatment-of-wastewater-containing-organic-substance.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="234136-recombinant-parainfluenza-virus-expression-systems-and-vaccines-comprising-heterologous-antigens-derived-from-metapneumovirus.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>234135</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>90/KOLNP/2006</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>19/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>08-May-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>06-May-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>10-Jan-2006</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>JOINT STOCK COMPANY GRINDEKS</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>KRUSTPILS STREET 53, LV-1057, RIGA, LATVIA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>KALVINSH, IVARS</td>
											<td>LIBIESHU STREET 25, LV-5052, IKSHKILE, LATVIA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>BIRMANS, ANATOLIJS</td>
											<td>OZOLCIEMA STREET, 46/3-15, LV-1058, RIGA</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07C 243/12</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/LV2004/000005</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2004-07-15</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>P-03-87</td>
									<td>2003-08-04</td>
								    <td>Latvia</td>
								</tr>
								<tr>
									<td>2</td>
									<td>P-03-88</td>
									<td>2003-08-04</td>
								    <td>Latvia</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/234135-meldonium-salts-process-for-their-preparation-and-pharmaceutical-composition-comprising-them by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 14:05:25 GMT -->
</html>
